Table 1.
Patient characteristics and clinical variables at baseline and after two months of treatment with sacubitril-valsartan.
| Baseline | 2-month | p value | |
|---|---|---|---|
| Age (years) | 69 ± 8 | - | |
| Height (cm) | 176.9 ± 9.2 | - | |
| Weight (kg) | 89.6 ± 12.8 | 90.6 ± 13.1 | 0.25 |
| Body mass index (kg/m2) | 28.6 ± 3.6 | 28.9 ± 3.7 | 0.21 |
| Heart rate (beats/min) | 66 ± 9 | 66 ± 6 | 0.81 |
| Total cholesterol (mg/dL) | 143 ± 50 | 149 ± 45 | 0.41 |
| HDL cholesterol (mg/dL) | 44 ± 13 | 40 ± 7 | 0.23 |
| LDL cholesterol (mg/dL) | 77 ± 36 | 80 ± 28 | 0.49 |
| Triglycerides (mg/dL) | 131 ± 75 | 154 ± 92 | 0.41 |
| Glucose (mg/dL) | 118 ± 45 | 104 ± 23 | 0.15 |
| Hemoglobin (g/dL) | 14.6 ± 1.1 | 14.7 ± 1.0 | 0.92 |
| Hematocrit (%) | 44.7 ± 3.1 | 44.4 ± 3.5 | 0.71 |
| Erythrocytes (M/μL) | 4.77 ± 0.40 | 4.74 ± 0.34 | 0.78 |
| Leukocytes (K/ μL) | 6.39 ± 2.12 | 5.89 ± 1.45 | 0.34 |
| Potassium (mmol/L) | 4.5 ± 0.4 | 4.2 ± 0.4 | 0.08 |
| Creatinine (mg/dL) | 1.45 ± 0.43 | 1.33 ± 0.41 | 0.17 |
| Albumin (g/dL) | 4.39 ± 0.21 | 4.31 ± 0.20 | 0.09 |
| eGFR (mL/min/1.73m2) | 54 ± 22 | 60 ± 22 | 0.22 |
| Total bilirubin (mg/dL) | 0.93 ± 0.33 | 0.89 ± 0.27 | 0.69 |
| Aspartate aminotransferase (IU/L) | 24.8 ± 7.5 | 22.1 ± 6.5 | 0.21 |
| Alanine aminotransferase (IU/L) | 24.0 ± 7.7 | 22.4 ± 6.4 | 0.48 |
| NT-proBNP (pg/mL) | 1542 ± 1143 | 1319 ± 1175 | 0.26 |
| BNP (pg/mL) | 138 ± 122 | 139 ± 153 | 0.95 |
| NT-proANP (ng/mL) | 27.5 ± 9.8 | 29.9 ± 12.7 | 0.43 |
| Troponin T (pg/mL) | 323 ± 313 | 276 ± 194 | 0.95 |
Data are mean ± SD (n = 9 for all, except NT-proBNP, BNP, and Troponin T (n = 8). HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; BNP, B-type natriuretic peptide; NT-proANP, N-terminal pro-atrial natriuretic peptide.